Patents by Inventor Thomas Pack
Thomas Pack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911382Abstract: There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.Type: GrantFiled: July 18, 2022Date of Patent: February 27, 2024Assignee: Altavant Sciences GmbHInventors: Steve Wring, Magdalena Alonso-Galicia, Thomas Pack, Julie Rurka, David Carpenter, Melissa Rhodes
-
Publication number: 20240024316Abstract: There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.Type: ApplicationFiled: January 4, 2023Publication date: January 25, 2024Inventors: Magdalena Alonso-Galicia, David Carpenter, Thomas Pack, Melissa Rhodes, Julie Rurka, Stephen Wring
-
Patent number: 11576915Abstract: There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.Type: GrantFiled: March 13, 2020Date of Patent: February 14, 2023Assignee: Altavant Sciences GmbHInventors: Magdalena Alonso-Galicia, David Carpenter, Thomas Pack, Melissa Rhodes, Julie Rurka, Steve Wring
-
Publication number: 20230000866Abstract: There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing.Type: ApplicationFiled: July 18, 2022Publication date: January 5, 2023Inventors: Steve Wring, Magdalena Alonso-Galicia, Thomas Pack, Julie Rurka, David Carpenter, Melissa Rhodes
-
Patent number: 11413287Abstract: There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day.Type: GrantFiled: November 15, 2019Date of Patent: August 16, 2022Assignee: ALTAVANT SCIENCES GmbHInventors: Steve Wring, Magdalena Alonso-Galicia, Thomas Pack, Julie Rurka, David Carpenter, Melissa Rhodes
-
Patent number: 11360096Abstract: Provided are methods for detecting protein interactions in a sample, the methods comprising: (a) detecting two or more polypeptides that when associated emit a first detectable signal in a first light emission spectrum; (b) contacting the two or more polypeptides with a third polypeptide conjugated to a dipole acceptor moiety that has a second light emission spectrum when excited within a light excitation spectrum, wherein the light excitation spectrum overlaps with the first light emission spectrum; and (c) detecting a second detectable signal emitted in the second light emission spectrum by the dipole acceptor moiety. Also provided are bioluminescent complexes comprising: (a) a first polypeptide conjugated to a dipole acceptor moiety, wherein the emits a first detectable signal in a first light emission spectrum.Type: GrantFiled: May 18, 2020Date of Patent: June 14, 2022Assignee: Duke UniversityInventors: Thomas Pack, Jeffrey Smith, Sudarshan Rajagopal, Marc Caron
-
Publication number: 20220096475Abstract: There is a method of treating or preventing sarcoidosis-associated pulmonary hypertension in a patient. The method has the step of administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing.Type: ApplicationFiled: October 21, 2021Publication date: March 31, 2022Inventors: Thomas PACK, Sudarshan Rajagopal
-
Publication number: 20220047594Abstract: There is a method of treating or preventing interstitial lung disease in a patient. The method includes the step of administering to the patient a therapeutically effective amount of the compound of the following formula: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 28, 2021Publication date: February 17, 2022Applicant: ALTAVANT SCIENCES GmbHInventors: Thomas PACK, Magdalena ALONSO-GALICIA
-
Patent number: 11208183Abstract: An emergency position indicating radio beacon that includes a waterproof rigid housing, antenna, a retention carriage strap securely mounted around its exterior periphery on a spool in a storage position. In an emergency the user can unwind the retention carriage strap and form an adjustable loop in the strap using hook and loop fasteners to firmly attach the strap connected to the EPIRB housing to the user's arm that allows a user to transport the radio beacon with the retention carriage strap in a hands-free configuration.Type: GrantFiled: June 2, 2015Date of Patent: December 28, 2021Assignee: ACR ELECTRONICS, INC.Inventors: Francisco Diaz, Ricardo Raimondo, Marlon Pinder, Thomas Pack
-
Patent number: 10923694Abstract: A protective metal enclosure box for lithium batteries that includes batteries subject to fire and explosion comprising a rigid metal covered box that includes an aluminum honeycomb grid core mesh that can receive multiple individual batteries spaced apart from each other and protected from each other thermally and from explosion. The protective battery pack box includes a pair of printed circuit boards for interacting with the batteries for transmitting voltage and amperage outside of said battery pack.Type: GrantFiled: February 1, 2017Date of Patent: February 16, 2021Assignee: ACR Electronics, IncInventors: Thomas Pack, William Cox, Ricardo Raimondo, Santiago Contreras
-
Publication number: 20200363424Abstract: Provided are methods for detecting protein interactions in a sample, the methods comprising: (a) detecting two or more polypeptides that when associated emit a first detectable signal in a first light emission spectrum; (b) contacting the two or more polypeptides with a third polypeptide conjugated to a dipole acceptor moiety that has a second light emission spectrum when excited within a light excitation spectrum, wherein the light excitation spectrum overlaps with the first light emission spectrum; and (c) detecting a second detectable signal emitted in the second light emission spectrum by the dipole acceptor moiety. Also provided are bioluminescent complexes comprising: (a) a first polypeptide conjugated to a dipole acceptor moiety, wherein the emits a first detectable signal in a first light emission spectrum.Type: ApplicationFiled: May 18, 2020Publication date: November 19, 2020Applicant: DUKE UNIVERSITYInventors: THOMAS PACK, JEFFREY SMITH, SUDARSHAN RAJAGOPAL, MARC CARON
-
Publication number: 20200289510Abstract: There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.Type: ApplicationFiled: March 13, 2020Publication date: September 17, 2020Inventors: Magdalena Alonso-Galicia, David Carpenter, Thomas Pack, Melissa Rhodes, Julie Rurka, Steve Wring
-
Publication number: 20200188399Abstract: There is a method of treating or preventing interstitial lung disease in a patient. The method includes the step of administering to the patient a therapeutically effective amount of the compound of the following formula: or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 13, 2019Publication date: June 18, 2020Applicant: ALTAVANT SCIENCES GmbHInventors: Thomas PACK, Magdalena ALONSO-GALICIA
-
Publication number: 20200188398Abstract: There is a method of treating or preventing sarcoidosis-associated pulmonary hypertension in a patient. The method has the step of administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing.Type: ApplicationFiled: December 13, 2019Publication date: June 18, 2020Applicant: ALTAVANT SCIENCES GmbHInventors: Thomas PACK, Sudarshan Rajagopal
-
Publication number: 20200155552Abstract: There is a method of treating or preventing pulmonary arterial hypertension or associated pulmonary arterial hypertension in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing.Type: ApplicationFiled: November 15, 2019Publication date: May 21, 2020Applicant: ALTAVANT SCIENCES GmbHInventors: Steve WRING, Magdalena ALONSO-GALICIA, Thomas PACK, Julie RURKA, David CARPENTER, Melissa RHODES
-
Patent number: 10236484Abstract: An external battery pack for protecting against a battery fire or battery explosion, said battery pack connectable to an emergency locator transmitter (ELT) typically mounted in an aircraft. The external replaceable battery pack has a protective metal enclosure and a removable metal cover. The box includes an aluminum honeycomb grid core mesh with passages, each sized to receive a single battery and a pair of printed circuit boards on top and bottom to receive battery power, voltage and current, from multiple batteries for use with an ELT. By using smaller and more batteries together, the possibility of a catastrophic failure is greatly eliminated or reduced in that a smaller battery have a lesser fire or explosion potential. The batteries are isolated from each other from excessive heat or destruction by explosion.Type: GrantFiled: February 1, 2017Date of Patent: March 19, 2019Assignee: ACR ELECTRONICS, INC.Inventors: Thomas Pack, William Cox, Ricardo Raimondo, Santiago Contreras
-
Publication number: 20160358448Abstract: An emergency position indicating radio beacon that includes a waterproof rigid housing, antenna, a retention carriage strap securely mounted around its exterior periphery on a spool in a storage position. In an emergency the user can unwind the retention carriage strap and form an adjustable loop in the strap using hook and loop fasteners to firmly attach the strap connected to the EPIRB housing to the user's arm that allows a user to transport the radio beacon with the retention carriage strap in a hands-free configuration.Type: ApplicationFiled: June 2, 2015Publication date: December 8, 2016Inventors: Francisco Diaz, Ricardo Raimondo, Marlon Pinder, Thomas Pack
-
Publication number: 20060142053Abstract: A communication device (10) in a clam shaped housing includes a camera (12) incorporated within a first portion (18) of the clam-shaped housing and a lens (14) incorporated within a second portion (19) of the clam-shaped housing. The camera and the lens can substantially align when the first portion pivots relative to the second portion. The lens can be an afocal converter lens that changes an effective focal length of a lens of the camera from among a wide angle, a telephoto, and a macro lens. The communication device can have at least one among a main display (15) on a flip portion of the communication device or an auxiliary display (16) on an opposing side (21) to enable viewing without the lens when the communication device is an open position and the auxiliary display can enable viewing with the lens when the communication device is in a closed position.Type: ApplicationFiled: December 15, 2004Publication date: June 29, 2006Applicant: Motorola, Inc.Inventors: Jorge Garcia, Habib Amirzadeh, Raymond Meenen, Thomas Pack